Testosterone therapy for functional hypogonadism in middle-aged and elderly males: current evidence and future perspectives.

Functional hypogonadism (FH) is defined as the combination of low testosterone levels with manifestations of hypogonadism in the absence of intrinsic pathology of the hypothalamic-pituitary-testicular axis.

• Low testosterone is typically defined as serum total testosterone below 300-350 ng/dL.
• FH is usually seen in middle-aged or elderly males as a product of aging and multimorbidity.
• FH differs from organic hypogonadism, which has an identifiable intrinsic pathology of the HPT axis.

Current clinical guidelines make only weak recommendations for testosterone therapy (TTh) in patients with functional hypogonadism.

• Guidelines mostly recommend TTh in FH in the presence of sexual dysfunction.
• Concerns about long-term safety have historically limited TTh use in middle-aged and elderly males with FH.
• TTh is the mainstay of treatment for organic hypogonadism but its role in FH remains more limited per guidelines.

Recent randomized controlled trials and meta-analyses have demonstrated safe long-term outcomes of TTh regarding prostatic and cardiovascular health in FH patients.

• Long-term safety outcomes included both prostatic health and cardiovascular health.
• Evidence comes from recent RCTs and meta-analyses, representing a shift from historical safety concerns.
• These findings support broader consideration of TTh in middle-aged and elderly males with FH.

Testosterone therapy has been associated with decreases in all-cause mortality in middle-aged and elderly males with functional hypogonadism.

• This finding was demonstrated in recent randomized controlled trials and meta-analyses.
• All-cause mortality reduction is identified as one of the key outcome improvements with TTh.
• This represents a significant clinical finding given the population aging context of the review.

Testosterone therapy produced improvements across multiple clinical domains including sexual function, body composition, physical strength, bone density, and hematopoiesis.

• Sexual function improvement is among the most established indications supported by current guidelines.
• Body composition and physical strength improvements are relevant to sarcopenia and frailty contexts.
• Bone density improvements have implications for fracture risk reduction.
• Hematopoietic effects were also identified as a beneficial outcome domain.

Multiple insightful studies suggest additional potential benefits of TTh in cardio-renal-metabolic conditions.

• Conditions identified include dyslipidemia, arterial hypertension, diabetes mellitus, heart failure, stable angina, and chronic kidney disease.
• These findings are characterized as 'insightful studies' suggesting benefits rather than established evidence.
• The authors note that future trials should investigate TTh's role in improving symptoms and prognosis in these clinical contexts.

Future trials are needed to investigate the role of TTh in sarcopenia, frailty, mood disorders, cognitive dysfunction, and fracture risk.

• The paper identifies sarcopenia and frailty as particularly relevant given the aging population context.
• Mood disorders and cognitive dysfunction are listed among conditions requiring future investigation.
• Fracture risk is identified as an additional domain where TTh effects warrant further study.
• These areas are highlighted as 'future perspectives' for testosterone therapy research.

Population aging is identified as a global phenomenon driving the clinical relevance of functional hypogonadism research.

• Age-related decline in testosterone levels has been associated with numerous adverse outcomes.
• FH is described as a product of both aging and multimorbidity, making it increasingly prevalent.
• The aging demographic context frames the public health significance of TTh evidence development.